Statins in combination with Ibrutinib bypasses resistance to Ibrutinib in mantle cell lymphoma
Overcoming chemoresistance to Ibrutinib
DOI:
https://doi.org/10.22317/jcms.v9i3.1330Keywords:
Statins, Ibrutinib, Chemoresistance, HMG-CoA reductase, Cholecterogenesis pathwayAbstract
Objective: In this study, we report that a novel combination therapy of different statins with Ibrutinib can overcome such resistance.
Methods: For this, we generated a cell line model, exhibiting resistance to Ibrutinib, by repeated exposure of mantle cell lymphoma cell line to Ibrutinib. Apoptosis was assessed by the extent of phosphatidylserine externalisation.
Results: Our results indicated that resistance to Ibrutinib could be overcome by targeting a key enzyme, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the cholesterogenesis pathway.
Conclusion: Reusing different statins in combination with Ibrutinib could improve therapy and enhance sensitivity to Ibrutinib mediated apoptosis.
References
Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Stilgenbauer S . Treatment of older patients with mantle-cell lymphoma.N Engl J Med
Aug 9; 367(6):520-31.
Dreyling M, Campo E, Hermine O, Jerkeman M, Gouill Le, Rule S, et al.Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017 July; 28(Supplement 4):iv62-71.
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks Bcell activation and is effificacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci 2010 Jul 20;107(29):13075-80.
Wiestner A.Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013 Jan 1; 31(1):128–30. Available from https: //pubmed.ncbi.nlm.nih.gov/23045586 DOI: 10.1200/JCO.2012.44.4281.
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature.2010 Jan 7;463(7277):88-92. Available from https://pubmed.ncbi.nlm.nih.gov/20054396// doi: 10.1038/nature08638. PMID: 20054396; PMCID: PMC2845535.
Kenkre VP & Kahl BS. The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways. Curr Hematol Malig Rep.2012 Sep; 7(3):216–20. Available from https://pubmed.ncbi.nlm.nih.gov/22688757/ doi: 10.1007/s11899-012-0127-0.
Buggy JJ & Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012 Apr;31 (2):119–32. doi:10.3109/08830185.2012.664797. Erratum in: Int Rev Immunol. 2012 Oct;31(5):428. PMID: 22449073.
Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signal. 2013 Jan; 25(1):106–12. doi:10.1016/j.cellsig.2012.09.008.
Harrison C. Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nat Rev Drug Discov. 2012 Jan 20;11(2):96. Avialable from https://pubmed.ncbi.nlm.nih.gov/22262035/ doi: 10.1038/nrd3656.
Alinari L, Christian B, Baiocchi RA, et al. Novel targeted therapies for mantle cell lymphoma. Oncotarget. 2012 Feb;3(2):203-11. Avialable from https://pubmed.ncbi.nlm.nih.gov/22361516/ doi: 10.18632/oncotarget.426.
Danilov AV. Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther. 2013 Sep;35(9):1258-70. Available from https://pubmed.ncbi.nlm.nih.gov/24054703/doi: 10.1016/j.clinthera.2013.08.004.
Stephens DM, Spurgeon SE. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol. 2015 Oct;6(5):242-52. Avialable from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556969/doi: 10.1177/2040620715592569.
Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018 Apr;35(4):309-318. Available from https://pubmed.ncbi.nlm.nih.gov/29799080/ doi: 10.1007/s10585-018-9903-0.
Li J, Eu JQ, Kong LR, Wang L, Lim YC, Goh BC, Wong ALA. Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. Molecules. 2020 Oct 20;25(20):4831. doi: 10.3390/molecules25204831.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, et al. Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 Jun 13;10(445):eaaq1240. doi: 10.1126/scitranslmed.aaq1240.
George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK, et al. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas. Cancers (Basel). 2020 May 22;12(5):1328. doi: 10.3390/cancers12051328.
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013 Oct;13(10):714-26. doi: 10.1038/nrc3599. PMID: 24060863.
McCann C, Kerr EM. Metabolic Reprogramming: A Friend or Foe to Cancer Therapy? Cancers (Basel). 2021 Jul 3;13(13):3351. doi: 10.3390/cancers13133351.
Galicia-Vázquez G, Aloyz R. Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes. Front Oncol. 2018 Sep 26;8:411. doi: 10.3389/fonc.2018.00411.
Li Z & Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016 Jan;73(2):377-92. doi: 10.1007/s00018-015-2070-4.
Monaco ME. Fatty acid metabolism in breast cancer subtypes. Oncotarget. 2017 Apr 25;8(17):29487-29500. doi: 10.18632/oncotarget.15494.
Al-Zebeeby A, Vogler M, Milani M, Richards C, Greaves G, Dyer MJS,et al. Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. Haematologica. 2019 May;104(5):1016-1025. doi: 10.3324/haematol.2018.204701.
Golomb BA & Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-418. doi: 10.2165/0129784-200808060-00004.
You HY, Zhang WJ, Xie XM, Zheng ZH, Zhu HL, Jiang FZ. Pitavastatin suppressed liver cancer cells in vitro and in vivo. Onco Targets Ther. 2016 Aug 29;9:5383-8. doi: 10.2147/OTT.S106906.
Soma M, Corsini A, Paoletti R. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. ToxicologyLetters. 1992 64;1–15.
Newman A, Clutterbuck RD, Powles RL, Catovsky D, Millar JL. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma. 1997 Feb;24(5-6):533-7. doi: 10.3109/10428199709055590.
Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001 Aug;22(8):1139-48. doi: 10.1093/carcin/22.8.1139.
Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs. 2001;19(1):81-3. doi: 10.1023/a:1006481423298.
Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist. 2006 Mar;11(3):306-15. doi: 10.1634/theoncologist.11-3-306.
Minden MD, Dimitroulakos J, Nohynek D, Penn LZ. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma. 2001 Feb;40(5-6):659-62. doi: 10.3109/10428190109097663.
Katz MS, Minsky BD, Saltz LB, Riedel E, Chessin DB, Guillem JG. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1363-70. doi: 10.1016/j.ijrobp.2004.12.033.
Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
Gimenez N, Tripathi R, Giró A, Rosich L, Lopez-Guerra M, Lopez-Oreja I, et al. Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. Sci Rep. 2020 Dec 17; 10: 22153.doi:10.1038/s41598-020-78315-0
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
